248 related articles for article (PubMed ID: 10490269)
1. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II).
Sasada T; Nakamura H; Ueda S; Sato N; Kitaoka Y; Gon Y; Takabayashi A; Spyrou G; Holmgren A; Yodoi J
Free Radic Biol Med; 1999 Sep; 27(5-6):504-14. PubMed ID: 10490269
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
Arnér ES; Nakamura H; Sasada T; Yodoi J; Holmgren A; Spyrou G
Free Radic Biol Med; 2001 Nov; 31(10):1170-8. PubMed ID: 11705695
[TBL] [Abstract][Full Text] [Related]
3. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
Huang J; Xu J; Tian L; Zhong L
Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
[TBL] [Abstract][Full Text] [Related]
4. Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum (II).
Sasada T; Nakamura H; Ueda S; Iwata S; Ueno M; Takabayashi A; Yodoi J
Antioxid Redox Signal; 2000; 2(4):695-705. PubMed ID: 11213475
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines.
Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T
Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187
[TBL] [Abstract][Full Text] [Related]
6. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
Montano SJ; Lu J; Gustafsson TN; Holmgren A
Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
8. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin Cross-Linking by Nitrogen Mustard in Lung Epithelial Cells: Formation of Multimeric Thioredoxin/Thioredoxin Reductase Complexes and Inhibition of Disulfide Reduction.
Jan YH; Heck DE; Casillas RP; Laskin DL; Laskin JD
Chem Res Toxicol; 2015 Nov; 28(11):2091-103. PubMed ID: 26451472
[TBL] [Abstract][Full Text] [Related]
10. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic characterization of the thioredoxin system in the removal of hydrogen peroxide.
Pannala VR; Dash RK
Free Radic Biol Med; 2015 Jan; 78():42-55. PubMed ID: 25451645
[TBL] [Abstract][Full Text] [Related]
12. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate.
Zhang H; Cao D; Cui W; Ji M; Qian X; Zhong L
Free Radic Biol Med; 2010 Dec; 49(12):2010-8. PubMed ID: 20951799
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines.
Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40(1):31-7. PubMed ID: 9137526
[TBL] [Abstract][Full Text] [Related]
14. Expression and distribution of thioredoxin and thioredoxin reductase in human nasal mucosa and nasal polyp.
Lee SH; Kim WS; Lee SH; Oh JW; Lee HM; Jung HH; Jang JW; Jun YJ; Cho WJ; Jhun HS
Acta Otolaryngol; 2005 Aug; 125(8):877-82. PubMed ID: 16158536
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo.
Fang J; Holmgren A
J Am Chem Soc; 2006 Feb; 128(6):1879-85. PubMed ID: 16464088
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma.
Kahlos K; Soini Y; Säily M; Koistinen P; Kakko S; Pääkkö P; Holmgren A; Kinnula VL
Int J Cancer; 2001 May; 95(3):198-204. PubMed ID: 11307155
[TBL] [Abstract][Full Text] [Related]
18. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin, thioredoxin reductase and tumour necrosis factor-alpha expression in melanoma cells: correlation to resistance against cytotoxic attack.
Barral AM; Källström R; Sander B; Rosén A
Melanoma Res; 2000 Aug; 10(4):331-43. PubMed ID: 10985667
[TBL] [Abstract][Full Text] [Related]
20. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.
Sasada T; Iwata S; Sato N; Kitaoka Y; Hirota K; Nakamura K; Nishiyama A; Taniguchi Y; Takabayashi A; Yodoi J
J Clin Invest; 1996 May; 97(10):2268-76. PubMed ID: 8636406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
